Literature DB >> 15289903

Evaluation of Fas gene promoter polymorphism in cervical cancer patients.

Aleksandra Dybikowska1, Wojciech Sliwinski, Janusz Emerich, Anna J Podhajska.   

Abstract

Transduction of signalling through Fas receptor has been implicated in physiological regulation of apoptosis process as well as pathogenesis of various human diseases. The gene encoding Fas receptor contains single nucleotide polymorphism at -670 position, which influences the expression by different transcriptional efficiency of this gene. The aim of this study was to determine the distribution of -670 A/G Fas gene promoter polymorphism in cervical cancer patients and healthy control group in Poland in order to evaluate the potential association between Fas genotype and cervical carcinogenesis. Our results do not confirm the hypothesis that AA genotype in Fas gene promoter may be engaged in the development of cervical neoplasia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289903

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  14 in total

1.  Significant association among the Fas -670 A/G (rs1800682) polymorphism and esophageal cancer, hepatocellular carcinoma, and prostate cancer susceptibility: a meta-analysis.

Authors:  Tao Liu; Li Zuo; Lin Li; Lei Yin; Kai Liang; Hongyuan Yu; Hui Ren; Wen Zhou; Hongwei Jing; Yang Liu; Chuize Kong
Journal:  Tumour Biol       Date:  2014-08-02

2.  Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma.

Authors:  Enrique Lerma; Marisa Romero; Alberto Gallardo; Cristina Pons; Josefina Muñoz; Josefina Fuentes; Belen Lloveras; Lluis Catasus; Jaime Prat
Journal:  Virchows Arch       Date:  2007-11-14       Impact factor: 4.064

Review 3.  Gene discovery in cervical cancer : towards diagnostic and therapeutic biomarkers.

Authors:  Cara M Martin; Louise Kehoe; Cathy O Spillane; John J O'Leary
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

4.  New approach reveals CD28 and IFNG gene interaction in the susceptibility to cervical cancer.

Authors:  Valeska B Guzman; Anatoly Yambartsev; Amador Goncalves-Primo; Ismael D C G Silva; Carmen R N Carvalho; Julisa C L Ribalta; Luiz Ricardo Goulart; Natalia Shulzhenko; Maria Gerbase-Delima; Andrey Morgun
Journal:  Hum Mol Genet       Date:  2008-03-12       Impact factor: 6.150

5.  FAS-670 gene polymorphism and cervical carcinogenesis risk: A meta-analysis.

Authors:  Qiaoying Huang; Jie Wang; Yanling Hu
Journal:  Biomed Rep       Date:  2013-08-20

6.  Genetic Polymorphism of Cancer Susceptibility Genes and HPV Infection in Cervical Carcinogenesis.

Authors:  Osamu Nunobiki; Masatsugu Ueda; Eisaku Toji; Michiko Yamamoto; Kyoko Akashi; Naomi Sato; Shinji Izuma; Kiyo Torii; Ichiro Tanaka; Yoshiaki Okamoto; Sadamu Noda
Journal:  Patholog Res Int       Date:  2011-05-31

7.  A comprehensive review on host genetic susceptibility to human papillomavirus infection and progression to cervical cancer.

Authors:  Koushik Chattopadhyay
Journal:  Indian J Hum Genet       Date:  2011-09

8.  FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer.

Authors:  Tong Sun; Yifeng Zhou; Hua Li; Xiaohong Han; Yuankai Shi; Li Wang; Xiaoping Miao; Wen Tan; Dan Zhao; Xuemei Zhang; Yongli Guo; Dongxin Lin
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307

9.  Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans.

Authors:  Koushik Chatterjee; Malin Engelmark; Ulf Gyllensten; Collet Dandara; Lize van der Merwe; Ushma Galal; Margaret Hoffman; Anna-Lise Williamson
Journal:  BMC Res Notes       Date:  2009-11-26

Review 10.  Germline polymorphism of cancer susceptibility genes in gynecologic cancer.

Authors:  Masatsugu Ueda; Eisaku Toji; Osamu Nunobiki; Shinji Izuma; Yoshiaki Okamoto; Kiyo Torii; Sadamu Noda
Journal:  Hum Cell       Date:  2008-11       Impact factor: 4.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.